Quick summary
Wormwood (Artemisia absinthium) is a plant with a long history in traditional medicine and has been the subject of various modern research investigations. It contains bioactive compounds such as flavonoids and sesquiterpene lactones which may have pharmacological activities. Research has explored its potential antimicrobial, anthelmintic, anti-inflammatory, anticancer, and metabolic disorder effects. While preclinical and ethnopharmacological evidence suggest possible benefits, high-quality clinical evidence remains limited. More rigorous studies are needed to confirm its efficacy and safety in humans.
What is it
Wormwood is a perennial herbaceous plant belonging to the Artemisia genus. It is native to temperate regions of Europe, Asia, and Northern Africa. Traditionally, wormwood has been used in various herbal preparations for medicinal purposes, culinary use, and in the production of beverages such as absinthe. The plant is known for its bitter compounds and aromatic essential oils.
Traditional uses
- Treatment of digestive issues including bloating and loss of appetite
- Use as an anthelmintic to expel intestinal worms
- Support for liver and gallbladder function
- Management of gastrointestinal disorders such as constipation-predominant irritable bowel syndrome (IBS-C)
- Folk remedies for infections and inflammation
Active compounds
- Flavonoids
- Sesquiterpene lactones (e.g., absinthin)
- Monoterpenes such as thujone, camphor, and pulegone
- Essential oils
Potential benefits with evidence levels
Anthelmintic activity
Moderate evidence from veterinary and animal studies, with some clinical trial data in livestock indicating efficacy comparable to standard antiparasitic agents.
- Anthelminthic medicinal plants in veterinary ethnopharmacology: A network meta-analysis (2020)
- Anthelmintic effects of Artemisia extracts on Ascaridia galli in poultry (2026)
Antimicrobial and antiparasitic potential
Preclinical and in vitro studies suggest potential antimicrobial properties. Enhanced antimicrobial activity has been observed using green-synthesized Artemisia-based nanoparticles.
- Enhanced Antimicrobial Activity of Green-Synthesized Artemisia-ZnO Nanoparticles (2025)
- Emerging Approaches to Anthelmintic Therapy Using Medicinal Plants (2025)
Potential anticancer activity
Preclinical studies and some clinical relevance have been suggested, though clinical trials are limited.
- Total Flavonoids in Artemisia absinthium L. and Evaluation of Its Anticancer Activity (2023)
- Research Advances on Health Effects of Edible Artemisia Species (2020)
Potential use in metabolic syndrome, diabetes, and cardiovascular conditions
Limited clinical studies exist, supported mostly by preclinical and traditional use evidence.
- Therapeutic Potential of Artemisia and Salvia Genera in Chronic Diseases (2025)
- Antidiabetic Activity of Medicinal Plants Used in Romania (2025)
Traditional and potential use in gastrointestinal disorders
Some limited and low-quality evidence from systematic reviews for herbal remedies in constipation-predominant irritable bowel syndrome (IBS-C), with no high-quality trials specifically on Artemisia.
Side effects
- Possible neurotoxicity and allergenic reactions related to monoterpene constituents such as thujone, camphor, and pulegone
- Potential toxicity, especially from monoterpene-rich essential oils
- Caution advised with prolonged or high-dose exposure
- Limited data available on adverse effects in clinical trials
Drug interactions
No clear evidence currently exists regarding specific drug interactions with wormwood. However, given its bioactive phytochemicals, potential interactions may exist but remain insufficiently characterized in clinical settings.
Who should avoid it
- Pregnant and breastfeeding women, due to insufficient safety data and known toxicity of some constituents (e.g., thujone)
- Individuals with neurological disorders, due to potential neurotoxic effects
- People sensitive to allergens or prone to allergic reactions from essential oils
- Use with medical supervision is recommended for at-risk groups
Evidence limitations
Most available data come from preclinical, in vitro, animal studies, and ethnopharmacological surveys. Clinical trials are sparse, often small-scale, and lack rigorous design. Variability in plant preparations, doses, and outcome measures limits the ability to conduct strong meta-analyses or draw definitive conclusions. High-quality, large-scale randomized controlled trials are needed to confirm efficacy and safety in humans.
References
- Anthelminthic medicinal plants in veterinary ethnopharmacology: A network meta-analysis (2020)
- Anthelmintic effects of Artemisia extracts on Ascaridia galli in poultry (2026)
- Enhanced Antimicrobial Activity of Green-Synthesized Artemisia-ZnO Nanoparticles (2025)
- Emerging Approaches to Anthelmintic Therapy Using Medicinal Plants (2025)
- Research Advances on Health Effects of Edible Artemisia Species (2020)
- Therapeutic Potential of Artemisia and Salvia Genera in Chronic Diseases (2025)
- Antidiabetic Activity of Medicinal Plants Used in Romania (2025)
- Herbal Remedies for Constipation-Predominant IBS: A Systematic Review (2023)
- Toxicity of Selected Monoterpenes and Essential Oils (2022)
- Significance of Artemisia Vulgaris L. in Medicine (2020)
- Current State of Research on Clinical Benefits of Herbal Medicines (2023)
Last reviewed
June 2024
Disclaimer: This information is provided for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before using any herbal products, especially if you are pregnant, breastfeeding, have existing health conditions, or are taking other medications.